Your browser doesn't support javascript.
ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets.
Marsh, Glenn A; McAuley, Alexander J; Au, Gough G; Riddell, Sarah; Layton, Daniel; Singanallur, Nagendrakumar B; Layton, Rachel; Payne, Jean; Durr, Peter A; Bender, Hannah; Barr, Jennifer A; Bingham, John; Boyd, Victoria; Brown, Sheree; Bruce, Matthew P; Burkett, Kathie; Eastwood, Teresa; Edwards, Sarah; Gough, Tamara; Halpin, Kim; Harper, Jenni; Holmes, Clare; Horman, William S J; van Vuren, Petrus Jansen; Lowther, Suzanne; Maynard, Kate; McAuley, Kristen D; Neave, Matthew J; Poole, Timothy; Rootes, Christina; Rowe, Brenton; Soldani, Elisha; Stevens, Vittoria; Stewart, Cameron R; Suen, Willy W; Tachedjian, Mary; Todd, Shawn; Trinidad, Lee; Walter, Duane; Watson, Naomi; Drew, Trevor W; Gilbert, Sarah C; Lambe, Teresa; Vasan, S S.
  • Marsh GA; CSIRO Australian Centre for Disease Preparedness, Geelong, VIC, Australia.
  • McAuley AJ; CSIRO Australian Centre for Disease Preparedness, Geelong, VIC, Australia.
  • Au GG; CSIRO Australian Centre for Disease Preparedness, Geelong, VIC, Australia.
  • Riddell S; CSIRO Australian Centre for Disease Preparedness, Geelong, VIC, Australia.
  • Layton D; CSIRO Australian Centre for Disease Preparedness, Geelong, VIC, Australia.
  • Singanallur NB; CSIRO Australian Centre for Disease Preparedness, Geelong, VIC, Australia.
  • Layton R; CSIRO Australian Centre for Disease Preparedness, Geelong, VIC, Australia.
  • Payne J; CSIRO Australian Centre for Disease Preparedness, Geelong, VIC, Australia.
  • Durr PA; CSIRO Australian Centre for Disease Preparedness, Geelong, VIC, Australia.
  • Bender H; CSIRO Australian Centre for Disease Preparedness, Geelong, VIC, Australia.
  • Barr JA; CSIRO Australian Centre for Disease Preparedness, Geelong, VIC, Australia.
  • Bingham J; CSIRO Australian Centre for Disease Preparedness, Geelong, VIC, Australia.
  • Boyd V; CSIRO Australian Centre for Disease Preparedness, Geelong, VIC, Australia.
  • Brown S; CSIRO Australian Centre for Disease Preparedness, Geelong, VIC, Australia.
  • Bruce MP; CSIRO Australian Centre for Disease Preparedness, Geelong, VIC, Australia.
  • Burkett K; CSIRO Australian Centre for Disease Preparedness, Geelong, VIC, Australia.
  • Eastwood T; CSIRO Australian Centre for Disease Preparedness, Geelong, VIC, Australia.
  • Edwards S; CSIRO Australian Centre for Disease Preparedness, Geelong, VIC, Australia.
  • Gough T; CSIRO Australian Centre for Disease Preparedness, Geelong, VIC, Australia.
  • Halpin K; CSIRO Australian Centre for Disease Preparedness, Geelong, VIC, Australia.
  • Harper J; CSIRO Australian Centre for Disease Preparedness, Geelong, VIC, Australia.
  • Holmes C; CSIRO Australian Centre for Disease Preparedness, Geelong, VIC, Australia.
  • Horman WSJ; CSIRO Australian Centre for Disease Preparedness, Geelong, VIC, Australia.
  • van Vuren PJ; CSIRO Australian Centre for Disease Preparedness, Geelong, VIC, Australia.
  • Lowther S; CSIRO Australian Centre for Disease Preparedness, Geelong, VIC, Australia.
  • Maynard K; CSIRO Australian Centre for Disease Preparedness, Geelong, VIC, Australia.
  • McAuley KD; CSIRO Australian Centre for Disease Preparedness, Geelong, VIC, Australia.
  • Neave MJ; CSIRO Australian Centre for Disease Preparedness, Geelong, VIC, Australia.
  • Poole T; CSIRO Australian Centre for Disease Preparedness, Geelong, VIC, Australia.
  • Rootes C; CSIRO Australian Centre for Disease Preparedness, Geelong, VIC, Australia.
  • Rowe B; CSIRO Australian Centre for Disease Preparedness, Geelong, VIC, Australia.
  • Soldani E; CSIRO Australian Centre for Disease Preparedness, Geelong, VIC, Australia.
  • Stevens V; CSIRO Australian Centre for Disease Preparedness, Geelong, VIC, Australia.
  • Stewart CR; CSIRO Australian Centre for Disease Preparedness, Geelong, VIC, Australia.
  • Suen WW; CSIRO Australian Centre for Disease Preparedness, Geelong, VIC, Australia.
  • Tachedjian M; CSIRO Australian Centre for Disease Preparedness, Geelong, VIC, Australia.
  • Todd S; CSIRO Australian Centre for Disease Preparedness, Geelong, VIC, Australia.
  • Trinidad L; CSIRO Australian Centre for Disease Preparedness, Geelong, VIC, Australia.
  • Walter D; CSIRO Australian Centre for Disease Preparedness, Geelong, VIC, Australia.
  • Watson N; CSIRO Australian Centre for Disease Preparedness, Geelong, VIC, Australia.
  • Drew TW; CSIRO Australian Centre for Disease Preparedness, Geelong, VIC, Australia.
  • Gilbert SC; Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Lambe T; Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Vasan SS; CSIRO Australian Centre for Disease Preparedness, Geelong, VIC, Australia. vasan.vasan@csiro.au.
NPJ Vaccines ; 6(1): 67, 2021 May 10.
Article in English | MEDLINE | ID: covidwho-1223093
ABSTRACT
Vaccines against SARS-CoV-2 are likely to be critical in the management of the ongoing pandemic. A number of candidates are in Phase III human clinical trials, including ChAdOx1 nCoV-19 (AZD1222), a replication-deficient chimpanzee adenovirus-vectored vaccine candidate. In preclinical trials, the efficacy of ChAdOx1 nCoV-19 against SARS-CoV-2 challenge was evaluated in a ferret model of infection. Groups of ferrets received either prime-only or prime-boost administration of ChAdOx1 nCoV-19 via the intramuscular or intranasal route. All ChAdOx1 nCoV-19 administration combinations resulted in significant reductions in viral loads in nasal-wash and oral swab samples. No vaccine-associated adverse events were observed associated with the ChAdOx1 nCoV-19 candidate, with the data from this study suggesting it could be an effective and safe vaccine against COVID-19. Our study also indicates the potential for intranasal administration as a way to further improve the efficacy of this leading vaccine candidate.
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Topics: Vaccines Language: English Journal: NPJ Vaccines Year: 2021 Document Type: Article Affiliation country: S41541-021-00315-6

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Topics: Vaccines Language: English Journal: NPJ Vaccines Year: 2021 Document Type: Article Affiliation country: S41541-021-00315-6